Protein detail
PRIO
Major prion protein (PrP) (ASCR) (PrP27-30) (PrP33-35C) (CD antigen CD230)
Entry name PRIO | UniProt ID | EVMP confidence score 0.88 |
Supporting publications (n) 21 | Transmembrane count | Protein classification CD markersDisease related genesHuman disease related genesPlasma proteinsPotential drug targetsPredicted membrane proteinsTransporters |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information11
Protein Names
Major prion protein (PrP) (ASCR) (PrP27-30) (PrP33-35C) (CD antigen CD230)
Protein Class (7)
CD markersDisease related genesHuman disease related genesPlasma proteinsPotential drug targetsPredicted membrane proteinsTransporters
Protein Function (5)
- Human disease related genes:Nervous system diseases:Neurodegenerative diseases
- CD markers
- Potential drug targets
- Transporters:Transporter channels and pores
- Disease related genes
Ensembl
Entrez Gene Symbol
Gene Synonym (6)
AltPrPCD230CJDGSSPRIPPRP
Gene Description
Prion protein
Chromosome
20
Position
4686350-4701590
Supporting publications (n)
21
EVMP confidence score
0.88
Fluorescence & Localization2
Tissue Specificskeletal muscleCell SpecificAlveolar cells type 1
Function & Pathway7
Protein Function (5)
- Human disease related genes:Nervous system diseases:Neurodegenerative diseases
- CD markers
- Potential drug targets
- Transporters:Transporter channels and pores
- Disease related genes
Cellular Component (18)
- GO:0005737 cytoplasm
- GO:0005741 mitochondrial outer membrane
- GO:0005783 endoplasmic reticulum
- GO:0005794 Golgi apparatus
- GO:0005829 cytosol
- GO:0005886 plasma membrane
- GO:0009897 external side of plasma membrane
- GO:0009986 cell surface
- GO:0014069 postsynaptic density
- GO:0016234 inclusion body
Page 1 of 2
Molecular Function (21)
- GO:0001540 amyloid-beta binding
- GO:0002020 protease binding
- GO:0005507 copper ion binding
- GO:0005515 protein binding
- GO:0005521 lamin binding
- GO:0005539 glycosaminoglycan binding
- GO:0008017 microtubule binding
- GO:0015631 tubulin binding
- GO:0019828 aspartic-type endopeptidase inhibitor activity
- GO:0031802 type 5 metabotropic glutamate receptor binding
Page 1 of 3
Biological Process (3)
KEGG (3)
Reactome (5)
Mediation Categories (6)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence70
Enzyme-Mediated Modification (2)
2 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| PRNP | CDK5 | Q00535 | S | 43 | phosphorylation | Sparser_ProtMapperPhosphoSitePhosphoSite_ProtMapperProtMapper | ProtMapper:19587281 |
| PRNP | CDK5R1 | Q15078 | S | 43 | phosphorylation | Sparser_ProtMapperProtMapper | ProtMapper:19587281ProtMapper:25572400 |
Ligand-Receptor Signaling (63)
63 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | GO_Intercell | No | Yes | No | Yes | Yes |
| receptor | receptor | OmniPath | No | Yes | No | Yes | Yes |
| extracellular | extracellular | DGIdb | No | No | No | Yes | Yes |
| extracellular | extracellular | DGIdb | No | No | No | Yes | Yes |
| extracellular | extracellular | OmniPath | No | No | No | Yes | Yes |
| extracellular | extracellular | OmniPath | No | No | No | Yes | Yes |
| intracellular | intracellular | ComPPI | No | No | No | Yes | Yes |
| intracellular | intracellular | ComPPI | No | No | No | Yes | Yes |
| intracellular | intracellular | GO_Intercell | No | No | No | Yes | Yes |
| intracellular | intracellular | UniProt_location | No | No | No | Yes | Yes |
Page 1 of 7Next
Regulatory Interaction Network (1)
1 record.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| CDK5 | Q00535 | PRIO | P04156 | Yes | Yes | No | iPTMnetSIGNORProtMapperPhosphoSitePhosphoSite_ProtMapper | PhosphoSite:25572400SIGNOR:19587281PhosphoSite:24360565 |
Protein Complex Composition (3)
3 records.
| Component Name | Component Gene Symbols | Component UniProt ID | Stoichiometry | Database | Database IDs | References |
|---|---|---|---|---|---|---|
| PRNP homo-oligomer complex | PRNP | P04156 | 2 | CORUMPDB | PDB:3nhdPDB:3md4PDB:3hesPDB:3md5PDB:7rl4PDB:3nhcPDB:6lniCORUM:2007PDB:3herPDB:7dwvPDB:3heqPDB:6uurPDB:3hj5PDB:4e1hPDB:7un5PDB:4e1iPDB:7rvjPDB:6pq5PDB:7umq | 16148934 |
| PRNP-ApolopoproteinE3 complex | APOEPRNP | P02649P04156 | 1:1 | Compleat | Compleat:HC2949 | 16764853 |
| PRNP-ApolopoproteinE3 complex | PRNPQ13791 | P04156Q13791 | 0:0 | CORUM | CORUM:1088 | 16764853 |
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential UltracentrifugationUltrafiltration / Tangential Flow Filtration | Mass spectrometry | 1 | 37786918 |
Sequence, Structure & Domains14
Sequences
Length
253
Mass
27,661
Sequence
MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG
Alternative Products
Event=Alternative initiation; Named isoforms=2; Name=1; Synonyms=PrP; IsoId=P04156-1; Sequence=Displayed; Name=3; Synonyms=AltPrP; IsoId=F7VJQ1-1; Sequence=External
3D Structural Models
Turn
74..76; 114..117; 171..173; 193..195; 223..225; 228..230
Helix
144..153; 154..156; 166..168
Beta Strand
63..67; 70..73; 79..82; 92..95; 99..101; 109..112; 118..122; 125..127; 128..131; 133..135; 138..140; 141..143; 159..163; 178..181; 182..185; 189..192; 196..202; 205..210; 212..215
3D Structure
Electron microscopy (11); NMR spectroscopy (34); X-ray crystallography (25)
Domain & Motif Annotations
Compositional Bias
52..95; Gly residues
Repeat
51..59; 1; 60..67; 2; 68..75; 3; 76..83; 4; 84..91; 5
Domain (CC)
The normal, monomeric form, PRPN(C), has a mainly alpha-helical structure. Misfolding of this form produces a disease-associated, protease-resistant form, PRPN (Sc), accompanied by a large increase of the beta-sheet content and formation of amyloid fibrils. These fibrils consist of a cross-beta spine, formed by a steric zipper of superposed beta-strands. Disease mutations may favor intermolecular contacts via short beta strands, and may thereby trigger oligomerization. In addition, the heparan-sulfate proteoglycan, GPC1, promotes the association of PRPN (C) to lipid rafts and appears to facilitate the conversion to PRPN (Sc).; DOMAIN: Contains an N-terminal region composed of octamer repeats. At low copper concentrations, the sidechains of His residues from three or four repeats contribute to the binding of a single copper ion. Alternatively, a copper ion can be bound by interaction with the sidechain and backbone amide nitrogen of a single His residue. The observed copper binding stoichiometry suggests that two repeat regions cooperate to stabilize the binding of a single copper ion. At higher copper concentrations, each octamer can bind one copper ion by interactions with the His sidechain and Gly backbone atoms. A mixture of binding types may occur, especially in the case of octamer repeat expansion. Copper binding may stabilize the conformation of this region and may promote oligomerization.
Region
23..230; Interaction with GRB2, ERI3 and SYN1; 23..38; Interaction with ADGRG6; 26..108; Disordered; 51..91; 5 X 8 AA tandem repeats of P-H-G-G-G-W-G-Q
Protein Families
Prion family
Sequence Similarities
Belongs to the prion family.
Clinical Relevance7
Disease Involvement (2)
AmyloidosisDisease variant
Drug Targets
Literature-reported target
Drugs
Interaction Protein (9)
ENSG00000022267ENSG00000103152ENSG00000129195ENSG00000155760ENSG00000163823ENSG00000164251ENSG00000169252ENSG00000169403ENSG00000173846
Interaction Count
9
Interaction Dataset
intact_biogrid
Supporting Publications19
| PMID | Title | Abstract |
|---|---|---|
| 23161513 | Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. | Exosomes from mutant KRAS cells contain many tumor-promoting proteins, including KRAS, EGFR, SRC family kinases, and integrins. |
| 27894104 | Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers. | No abstract available |
| 28369848 | End stage renal disease-induced hypercalcemia may promote aortic valve calcification via Annexin VI enrichment of valve interstitial cell derived-matrix vesicles. | No abstract available |
| 28986585 | Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics. | No abstract available |
| 29045505 | Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. | Proteomic analysis of the exosome 'surfaceome' revealed multiple PDAC-specific biomarker candidates: CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE, and HIST2H2BF. Droplet digital PCR was used on 74 patients (136 total exosome samples) to determine baseline KRAS mutation call rates while patients were on therapy. KRAS mutations in total exosomes were detected in 44.1% of patients undergoing active therapy compared with 73.0% following exosome capture using the selected biomarkers. |
| 31018934 | Proteomic Analysis of Urinary Microvesicles and Exosomes in Medullary Sponge Kidney Disease and Autosomal Dominant Polycystic Kidney Disease. | No abstract available |
| 32089743 | Human umbilical cord mesenchymal stromal cells-derived extracellular vesicles exert potent bone protective effects by CLEC11A-mediated regulation of bone metabolism. | No abstract available |
| 32284825 | Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine. | No abstract available |
| 32795414 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. | Among traditional exosome markers, CD9, HSPA8, ALIX, and HSP90AB1 represent pan-EVP markers, while ACTB, MSN, and RAP1B are novel pan-EVP markers. |
| 34186243 | A Reductionist Approach Using Primary and Metastatic Cell-Derived Extracellular Vesicles Reveals Hub Proteins Associated with Oral Cancer Prognosis. | No abstract available |
Page 1 of 2Next